Form 4: KORU Medical Director Acquires Shares

KORU Medical Systems Director Donna French acquired 2,581 shares of common stock at $5.81 per share, increasing her beneficial ownership to 91,471 shares.

Summary

• Donna French, a Director of KORU Medical Systems, Inc. (KRMD), acquired 2,581 shares of the company's common stock.
• The transaction occurred on January 2, 2026, at a price of $5.81 per share.
• Following this acquisition, Donna French beneficially owns a total of 91,471 shares of KORU Medical Systems common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director is generally a positive signal, indicating management's confidence in the company's future. The transaction being part of a 10b5-1 plan suggests a pre-meditated investment.

Positives

• A Director's acquisition of company stock signals confidence in the company's future prospects and valuation.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-planned investment strategy rather than a reaction to immediate market events.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

Insider buying, particularly by a director, is often viewed by the market as a positive indicator, suggesting that those with intimate knowledge of the company believe its stock is undervalued or poised for growth. This transaction aligns with general market observations where insider confidence can influence investor sentiment.

Stakeholder Impact

• Shareholders may interpret this insider purchase as a positive sign, potentially boosting investor confidence and demand for the stock.
• Employees might view this as a sign of stability and positive outlook from leadership.

Key Dates

Recommendation

While a director's purchase of company stock is a positive signal, indicating confidence in the company's prospects, this single transaction of 2,581 shares, even at a specific price, is not substantial enough on its own to warrant a 'buy' recommendation for a seasoned investor. It reinforces a 'hold' position for existing investors and suggests a positive sentiment, but further fundamental analysis and broader market context would be required for a stronger recommendation.

Keywords

KORU Medical Systems, KRMD, Insider Trading, Form 4, Stock Acquisition, Director, Donna French, 10b5-1 Plan